Navigation Links
Kallestad ENA Screen (six antigens per well),

ProductsKallestad ENA Screen (six antigens per well),
Company Bio-Rad Laboratories
Item Kallestad ENA Screen (six antigens per well),
Features 
  • 96 Tests Per Kit
    • Description The ANA and ENA assays can be used to screen out patients negative for antinuclear antibodies, which are associated with various systemic rheumatic diseases such as Systemic lupus erythematosus (Lupus), Sjgren's syndrome, mixed connective tissue disease, progressive systemic sclerosis, scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. They can also be used in conjunction with our individual antibody assays to identify specific autoantibodies.
    Info Bio-Rad Laboratories
    Customer Service: 1-800-2-BIORAD
    Web site: http://www.bio-rad.com

    Related medicine products :

    1. Kallestad Anti-Thyroglobulin (Tg)
    2. Kallestad Anti-Thyroid Peroxidase (TPO)
    3. Kallestad ANA Screen
    4. Automatic Tangent Screen
    5. 1-Meter Roll-Up Tangent Screen
    6. Welch Allyn Suresight™ Vision Screener (English)
    7. ENA Screen EIA Auto-Immune Markers 012-MDKES1 Extractable Nuclear Antigens
    8. Topcon SS-3 Screenoscope
    9. Screenline LCD Monitors
    10. DiaScreen 50 Urine Chemistry Analyzer
    11. Hema Screen™
    New Image Cut-to-Fit Convex FlexWear Skin Barrier
    New Image Closed Mini Pouch
    CenterPointLock Stoma Irrigator Drain
    CenterPointLock Sterile Drainable Kits
    Medicine Products:
    (Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
    (Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
    (Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
    (Date:12/4/2009)Outcomes same whether procedure done immediately or 3 weeks later, study shows , , FRIDAY, Dec. 4 (HealthDay News) -- Timing of surgical repair or reconstruction of multiple-ligament knee inju
    (Date:12/4/2009)BOSTON, Dec. 4 Substantial progress has been made over the last 15 years in the healthcare community,s ability to diagnose and treat epilepsy and its complications. Yet this progress in epilepsy man
    Breaking Medicine News(10 mins):Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4
    ...dical, Inc.(TM), a leading medical technology comp...heral vascular disease, has completed the first hu...rossBoss(TM) CTO Catheter and Stingray(TM) CTO Re-... the treatment of completely blocked arteries know...
    ...rency firm change:healthcare has a prescription th...healthcare and financial distress. , ...9 -- The disappearance of 3.6 million jobs since D...the unpredictable cost of medical care can not onl...
    ...ties more supportive of stem cell research funding... A new national study conducted among 962 physicia... supportive of stem cell research than consumers a...e than half (55%) reported that they agree with fe...
    ...revention has improved, mortality rates are down, ...irculation from the Framingham Heart Study, which...nce in 9824 men and women over four decades, has p...d that over the past 40 years rates of AMI diagnos...
    ..., Inc. (OTC Bulletin Board: EMED), a leading provi...he Medical and Dental industries, has signed a con...l solutions to AmeriPlan(R) Corporation,s national... drugs, chiropractic, podiatry, medical, hospital ...
    ...l Alliance on Mental Illness (NAMI) Michigan relea...e state of mental health care in our state. The S...e in its rating . Fourteen states improved their g... further this year," said Sherri Solomon, Executiv...
    Other Medicine News:Health News:BridgePoint Medical Completes First U.S. Clinical Case Using CrossBoss and Stingray Devices in CTO Angioplasty Procedure 2Health News:change:healthcare Helps Displaced Employees Immobilized by High Cost of Healthcare 2Health News:change:healthcare Helps Displaced Employees Immobilized by High Cost of Healthcare 3Health News:Docs More Supportive of Stem Cell Research Funding Than Consumers After Viewing President's Speech 2Health News:Docs More Supportive of Stem Cell Research Funding Than Consumers After Viewing President's Speech 3Health News:Explaining trends in heart attack 2Health News:MedCom Signs National Provider Contract With AmeriPlan Corporation 2Health News:MedCom Signs National Provider Contract With AmeriPlan Corporation 3Health News:Michigan's Mental Health Care System Gets a D Grade in Latest Study 2
    (Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
    (Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
    (Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
    Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Childbirth May Slow Progression of Multiple Sclerosis 62015 1Childbirth May Slow Progression of Multiple Sclerosis 62015 2Childbirth May Slow Progression of Multiple Sclerosis 62015 3DNA Genotek Launches Global Partner Program 14953 1DNA Genotek Launches Global Partner Program 14953 2DNA Genotek Launches Global Partner Program 14953 3Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 1Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 2Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 3